Trials / Completed
CompletedNCT04999449
Nebulizer Delivery of Intranasal Scopolamine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Dartmouth-Hitchcock Medical Center · Academic / Other
- Sex
- All
- Age
- 21 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.
Detailed description
An aqueous scopolamine formulation is being administered via a nebulizer and the pharmacokinetics of the drug are being measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Scopolamine | Intranasal scopolamine at 0.2 mg or 0.4 mg |
| DRUG | Placebo | Intranasal saline placebo |
Timeline
- Start date
- 2022-01-24
- Primary completion
- 2025-05-07
- Completion
- 2025-05-07
- First posted
- 2021-08-10
- Last updated
- 2025-08-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04999449. Inclusion in this directory is not an endorsement.